EUVIMEDEUVIMED entdecken
Multizentrische Studie

Triplet chemotherapy with or without bevacizumab as first line treatment for metastatic colorectal cancer: An AGEO multicenter real-world study

R Varnier, C Toullec, S Philonenko, A Dupré, P Artru, E Hafliger, A Drouillard, C Torregrosa, S Pernot, P McLellan, T Lecomte, V Moulin und 5 weitere

Digestive and Liver Disease · 2024-09 · 56 (9) · 1605-1613

DOI: 10.1016/j.dld.2024.02.009 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Digestive and Liver Disease, 2024-09. Verfasst von R Varnier und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Centre Léon Bérard, Lyon, France; Research on Healthcare Performance (RESHAPE, Inserm U1290), Université Claude Berna…. Hauptthemen laut MEDLINE: Bevacizumab, Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BevacizumabColorectal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleRetrospective StudiesAgedMiddle AgedFranceAntineoplastic Agents, ImmunologicalProgression-Free SurvivalAdultAged, 80 and over

Stichwörter der Autor:innen

BevacizumabColorectal cancerFOLFOXIRITriplet chemotherapy

Substanzen

BevacizumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Medical Oncology, Centre Léon Bérard, Lyon, France; Research on Healthcare Performance (RESHAPE, Inserm U1290), Université Claude Bernard Lyon 1, Lyon, France.
  • Department of Digestive Oncology, Institut du Cancer Avignon-Provence, Avignon, France.
  • Department of Gastroenterology and Digestive Oncology, Hôpital Pitié Salpêtrière, Paris, France.
  • Department of Surgery, Centre Léon Bérard, Lyon, France.
  • Department of Gastroenterology and Digestive Oncology, Hôpital Privé Jean Mermoz, Lyon, France.
  • Department of Hepato-Gastroenterology and Digestive Oncology, Centre Hospitalier Universitaire de Dijon, Dijon, France.

Zitieren

APA

Varnier, R., Toullec, C., Philonenko, S., Dupré, A., Artru, P., Hafliger, E., Drouillard, A., Torregrosa, C., Pernot, S., McLellan, P., Lecomte, T., Moulin, V., Lécaille, C., Touchefeu, Y., Locher, C., Taieb, J., & Coutzac, C. (2024). Triplet chemotherapy with or without bevacizumab as first line treatment for metastatic colorectal cancer: An AGEO multicenter real-world study. Digestive and Liver Disease, 56(9), 1605-1613. https://doi.org/10.1016/j.dld.2024.02.009

Vancouver

Varnier R, Toullec C, Philonenko S, Dupré A, Artru P, Hafliger E, et al. Triplet chemotherapy with or without bevacizumab as first line treatment for metastatic colorectal cancer: An AGEO multicenter real-world study. Digestive and Liver Disease. 2024;56(9):1605-1613. doi:10.1016/j.dld.2024.02.009

BibTeX
@article{Varnier2024,
  author = {Varnier, R and Toullec, C and Philonenko, S and Dupré, A and Artru, P and Hafliger, E and Drouillard, A and Torregrosa, C and Pernot, S and McLellan, P and Lecomte, T and Moulin, V and Lécaille, C and Touchefeu, Y and Locher, C and Taieb, J and Coutzac, C},
  title = {Triplet chemotherapy with or without bevacizumab as first line treatment for metastatic colorectal cancer: An AGEO multicenter real-world study},
  journal = {Digestive and Liver Disease},
  year = {2024},
  volume = {56},
  number = {9},
  pages = {1605--1613},
  doi = {10.1016/j.dld.2024.02.009}
}
Kostenlos starten →